Daratumumab May Benefit Patients With Refractory Multiple Myeloma
June 16th 2015In a heavily pretreated multiple myeloma (MM) population, daratumumab monotherapy at 16 mg/kg showed meaningful, durable, single-agent activity, with deep responses and a favorable safety profile, according to a new phase II study.